Phaseline

Companies › Resurge Therapeutics

Resurge Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RT-310
Locally-acting implant for prostate gland treatment
–Phase 1BPH (Benign Prostatic Hyperplasia)Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06136819RT-310Phase 1BPH (Benign Prostatic Hyperplasia)GenitourinaryNov 2026
NCT07264205RT-310Phase 1BPH (Benign Prostatic Hyperplasia)GenitourinaryAug 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.